Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
Mello
Michelle M
MM
Department of Health Policy and Management, Harvard School of Public Health, Boston, USA.
Studdert
David M
DM
Brennan
Troyen A
TA
D017277:Drug Approval / Q000266:history / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000266:history / Q000331:legislation & jurisprudence*; D004348:Drug Labeling / Q000331:legislation & jurisprudence*; D004502:Education, Medical, Continuing / Q000331:legislation & jurisprudence; D033161:Government Regulation / Q000266:history; D017408:Guidelines as Topic; D006291:Health Policy / Q000266:history / Q000331:legislation & jurisprudence; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D040541:Marketing / Q000266:history / Q000331:legislation & jurisprudence*; D011358:Product Surveillance, Postmarketing; D017594:Publication Bias; D014481:United States; D014486:United States Food and Drug Administration / Q000266:history